Advertisement

 

 

Expression of Interleukin-17 in Primary Sjögren’s Syndrome and the Correlation with Disease Severity: A Systematic Review and Meta-Analysis.

Expression of Interleukin-17 in Primary Sjögren’s Syndrome and the Correlation with Disease Severity: A Systematic Review and Meta-Analysis.
Author Information (click to view)

Zhang LW, Zhou PR, Wei P, Cong X, Wu LL, Hua H,


Zhang LW, Zhou PR, Wei P, Cong X, Wu LL, Hua H, (click to view)

Zhang LW, Zhou PR, Wei P, Cong X, Wu LL, Hua H,

Advertisement

Scandinavian journal of immunology 2018 02 24() doi 10.1111/sji.12649
Abstract

The aberrant expression of interleukin-17 (IL-17) has been reported in primary Sjögren’s syndrome (pSS). Abnormalities in IL-17 can promote the production of pro-inflammatory cytokines and aggravate autoimmune disorders. The aim of this study is to investigate alterations of IL-17 in pSS patients, and explore the correlation between IL-17 and disease severity. Eight databases are searched for original studies reporting the expression of IL-17 in pSS patients and controls. Eligible reports are included in the pooled analysis, and subgroup evaluations are performed according to different types of controls and IL-17 measurement methods. Newcastle-Ottawa Scale criteria are used to assess the risk of bias of the included studies. In total, 45 articles are included in the meta-analysis. The expression of IL-17 is significantly increased in pSS patients compared to controls. Furthermore, pSS patients without immunosuppressive treatment show markedly higher IL-17 levels. In addition, pSS patients with positive rheumatoid factors tend to express a higher level of IL-17 than patients with negative rheumatoid factors. Negative correlations between IL-17 levels and ocular parameters are also found in pSS patients. The results are similar after adjustment by "trim and fill" methods. In conclusion, the expression of IL-17 is obviously increased in pSS patients, especially among those without immunosuppressive treatment. In addition, IL-17 level correlates with the disease severity of pSS. These findings demonstrate the significance of IL-17 overexpression in pSS patients, and may provide insights for the development of therapeutic interventions targeting IL-17 for pSS. This article is protected by copyright. All rights reserved.

Submit a Comment

Your email address will not be published. Required fields are marked *

ten − five =

[ HIDE/SHOW ]